[go: up one dir, main page]

DE69939821D1 - Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten - Google Patents

Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten

Info

Publication number
DE69939821D1
DE69939821D1 DE69939821T DE69939821T DE69939821D1 DE 69939821 D1 DE69939821 D1 DE 69939821D1 DE 69939821 T DE69939821 T DE 69939821T DE 69939821 T DE69939821 T DE 69939821T DE 69939821 D1 DE69939821 D1 DE 69939821D1
Authority
DE
Germany
Prior art keywords
csf
present
apc
tumor
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69939821T
Other languages
English (en)
Inventor
Michael Derek Roth
Robert Alan Figlin
Sylvia Marie Kiertscher
Barbara Jennifer Gitlitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE69939821D1 publication Critical patent/DE69939821D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2026IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69939821T 1998-04-02 1999-04-02 Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten Expired - Fee Related DE69939821D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8051298P 1998-04-02 1998-04-02
US11578899P 1999-01-13 1999-01-13
PCT/US1999/007376 WO1999051257A1 (en) 1998-04-02 1999-04-02 Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient

Publications (1)

Publication Number Publication Date
DE69939821D1 true DE69939821D1 (de) 2008-12-11

Family

ID=26763616

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939821T Expired - Fee Related DE69939821D1 (de) 1998-04-02 1999-04-02 Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten

Country Status (7)

Country Link
EP (1) EP1076564B1 (de)
JP (1) JP2002510642A (de)
AT (1) ATE412418T1 (de)
AU (1) AU748850B2 (de)
CA (1) CA2326739A1 (de)
DE (1) DE69939821D1 (de)
WO (1) WO1999051257A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1305041E (pt) * 2000-07-28 2006-09-29 Liponova Ag Medicamento para a imunoterapia de tumores malignos
US20020094323A1 (en) 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2014066443A1 (en) * 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US10842743B2 (en) 2016-04-08 2020-11-24 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
AU4818297A (en) * 1996-10-16 1998-05-11 Johns Hopkins University, The Cytokine enhanced immunotherapy for brain tumors

Also Published As

Publication number Publication date
EP1076564A4 (de) 2005-02-23
CA2326739A1 (en) 1999-10-14
WO1999051257A1 (en) 1999-10-14
EP1076564A1 (de) 2001-02-21
AU3469599A (en) 1999-10-25
JP2002510642A (ja) 2002-04-09
AU748850B2 (en) 2002-06-13
EP1076564B1 (de) 2008-10-29
ATE412418T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
ES2298418T3 (es) Procedimiento para la preparacion de una libreria de arnm de antigenos tumorales.
Wong Oral complications and management strategies for patients undergoing cancer therapy
Dilsiz et al. Capillary hemangioma as a rare benign tumor of the oral cavity: a case report
CA2727388C (en) Telomerase-derived peptides for use in treatment of cancer
JP2020023525A (ja) ペプチド混合物
HUP0303125A2 (hu) Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel
IL169002A (en) A preparation containing partially dendritic cells in vitro
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
Huang et al. Autologous transplantation of deciduous tooth pulp into necrotic young permanent teeth for pulp regeneration in a dog model
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
DE69939821D1 (de) Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
Fioramonti et al. A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
RU2335539C2 (ru) Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации
MY141122A (en) Vaccine composition containing transforming growth factor alpha (tgf[alpha]). it use in malignant diseases therapy
Suntharalingam et al. The use of concurrent chemotherapy with high-dose radiation before surgical resection in patients presenting with apical sulcus tumors.
Le et al. A case of dyskeratosis congenita with squamous cell carcinoma of the maxilla: a case report and review of the literature
Brownson et al. CXI Ewing's Sarcoma of the Maxilla
TWI347194B (en) Alpha-emitting hydroxyapatite particles
Koranne et al. Keratoameloblastoma-A Rare hybrid odontogenic tumor
Casu et al. Photodynamic Therapy in Non-Responsive Oral Angular Cheilitis: 4 Case Reports
Hascoet et al. Ameloblastic fibrosarcoma of the mandible: case report and literature review
ES2791410T3 (es) Uso de composiciones inmunomoduladoras eficaces para el tratamiento inmunoterápico de pacientes que padecen leucemias mielógenas
Saleh et al. The oral surgeon in the front-line of the diagnosis of Ewing sarcoma: a case report

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee